Westfield Capital Management’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.28B | Sell |
4,798,267
-15,173
| -0.3% | -$3.54M | 4.18% | 3 |
|
|
2026
Q1 | $1.1B | Sell |
4,813,440
-372,256
| -7% | -$83.4M | 4.62% | 2 |
|
|
2025
Q4 | $1.11B | Sell |
5,185,696
-74,213
| -1% | -$15.3M | 4.61% | 2 |
|
|
2025
Q3 | $1.05B | Sell |
5,259,909
-191,492
| -4% | -$35.7M | 4.39% | 2 |
|
|
2025
Q2 | $941M | Sell |
5,451,401
-27,858
| -0.5% | -$4.54M | 3.95% | 2 |
|
|
2025
Q1 | $854M | Sell |
5,479,259
-48,980
| -0.9% | -$7M | 4.16% | 1 |
|
|
2024
Q4 | $761M | Buy |
5,528,239
+394,473
| +8% | +$51.9M | 3.31% | 4 |
|
|
2024
Q3 | $767M | Buy |
5,133,766
+170,942
| +3% | +$23.1M | 3.46% | 4 |
|
|
2024
Q2 | $677M | Buy |
4,962,824
+887,610
| +22% | +$121M | 3.33% | 4 |
|
|
2024
Q1 | $616M | Buy |
4,075,214
+44,580
| +1% | +$6.36M | 3.23% | 2 |
|
|
2023
Q4 | $508M | Buy |
4,030,634
+228,457
| +6% | +$22.8M | 2.96% | 2 |
|
|
2023
Q3 | $356M | Buy |
3,802,177
+170,465
| +5% | +$15.9M | 2.43% | 4 |
|
|
2023
Q2 | $324M | Buy |
3,631,712
+485,586
| +15% | +$42.3M | 2.06% | 6 |
|
|
2023
Q1 | $337M | Sell |
3,146,126
-12,042
| -0.4% | -$1.38M | 2.38% | 3 |
|
|
2022
Q4 | $386M | Buy |
3,158,168
+247,444
| +9% | +$28.7M | 2.98% | 2 |
|
|
2022
Q3 | $301M | Buy |
2,910,724
+122,415
| +4% | +$11.6M | 2.39% | 4 |
|
|
2022
Q2 | $259M | Buy |
2,788,309
+153,282
| +6% | +$14.4M | 2.04% | 5 |
|
|
2022
Q1 | $309M | Sell |
2,635,027
-5,907
| -0.2% | -$684K | 1.98% | 6 |
|
|
2021
Q4 | $355M | Buy |
2,640,934
+529,441
| +25% | +$78.8M | 2.11% | 6 |
|
|
2021
Q3 | $337M | Buy |
2,111,493
+95,566
| +5% | +$13.1M | 2.03% | 6 |
|
|
2021
Q2 | $265M | Buy |
2,015,927
+148,234
| +8% | +$19.8M | 1.59% | 8 |
|
|
2021
Q1 | $241M | Buy |
1,867,693
+137,812
| +8% | +$20.9M | 1.5% | 8 |
|
|
2020
Q4 | $289M | Sell |
1,729,881
-59,893
| -3% | -$9.9M | 1.71% | 7 |
|
|
2020
Q3 | $276M | Buy |
1,789,774
+351,109
| +24% | +$50.5M | 1.79% | 6 |
|
|
2020
Q2 | $213M | Buy |
1,438,665
+75,323
| +6% | +$10.3M | 1.46% | 10 |
|
|
2020
Q1 | $154M | Buy |
1,363,342
+102,586
| +8% | +$13.3M | 1.35% | 12 |
|
|
2019
Q4 | $175M | Buy |
1,260,756
+136,702
| +12% | +$15.2M | 1.25% | 15 |
|
|
2019
Q3 | $108M | Buy |
1,124,054
+152,302
| +16% | +$17M | 0.87% | 27 |
|
|
2019
Q2 | $112M | Buy |
971,752
+285,207
| +42% | +$34.1M | 0.84% | 33 |
|
|
2019
Q1 | $80.8M | Buy |
686,545
+147,425
| +27% | +$12.9M | 0.61% | 58 |
|
|
2018
Q4 | $33.8M | Sell |
539,120
-42,614
| -7% | -$2.68M | 0.29% | 109 |
|
|
2018
Q3 | $41.2M | Buy |
581,734
+157,159
| +37% | +$10.8M | 0.29% | 117 |
|
|
2018
Q2 | $28.2M | Buy |
+424,575
| New | +$27.9M | 0.21% | 154 |
|
Other funds holding ASND
RCM
ACA
JT
Westfield Capital Management's ASND Position: Q2 2026 in Review
Westfield Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 0.32% in Q2 2026, selling an estimated $3.54M and leaving 4,798,267 shares worth $1.28B. The position accounts for 4.18% of the portfolio, ranked #3.
Westfield Capital Management first reported a position in ASND in Q2 2018 and has held it in 33 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Westfield Capital Management held 4,798,267 shares of Ascendis Pharma A/S worth $1.28B as of Q2 2026.
- Westfield Capital Management sold 15,173 Ascendis Pharma A/S shares in Q2 2026, an estimated $3.54M.
- Ascendis Pharma A/S made up 4.18% of Westfield Capital Management's portfolio in Q2 2026, its #3 holding.
- Westfield Capital Management first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 33 quarters since.
- 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.